Orion Capital Management LLC Makes New $649,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Posted by Brian Himes on Aug 29th, 2026

Orion Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,155 shares of the biopharmaceutical company’s stock, valued at approximately $649,000.

Several other institutional investors also recently bought and sold shares of the stock. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $27,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. Citigroup decreased their price objective on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. BMO Capital Markets began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 19th. They set an “outperform” rating and a $318.00 target price on the stock. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Barclays reduced their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.14.

Check Out Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $237.10 on Friday. The firm’s fifty day moving average price is $262.62 and its 200 day moving average price is $293.73. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm has a market cap of $31.73 billion, a price-to-earnings ratio of 44.07 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the company posted ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.